The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Vitravene fomivirsen | Novartis Ophthalmics Europe Ltd. | Cytomegalovirus Retinitis; HIV Infections | 🇪🇺 EU 1999-07-29 | Order → |
| Zeffix lamivudine | GlaxoSmithKline Trading Services Limited | Hepatitis B, Chronic | 🇪🇺 EU 1999-07-29 | Order → |
| Paxene paclitaxel | Norton Healthcare Ltd. | Sarcoma, Kaposi; Carcinoma, Non-Small-Cell Lung; Ovarian Neoplasms; Breast Neoplasms | 🇪🇺 EU 1999-07-19 | Order → |
| Ziagen abacavir | ViiV Healthcare B.V. | HIV Infections | 🇪🇺 EU 1999-07-08 | Order → |
| Integrilin eptifibatide | GlaxoSmithKline Trading Services Limited | Angina, Unstable; Myocardial Infarction | 🇪🇺 EU 1999-07-01 | Order → |
| Stocrin efavirenz | Merck Sharp & Dohme B.V. | HIV Infections | 🇪🇺 EU 1999-05-28 | Order → |
| Sustiva efavirenz | Bristol-Myers Squibb Pharma EEIG | HIV Infections | 🇪🇺 EU 1999-05-28 | Order → |
| Cotronak ribavirin | Schering-Plough Europe | Hepatitis C, Chronic | 🇪🇺 EU 1999-05-07 | Order → |
| Procomvax haemophilus B conjugate (meningococcal protein conjugate) and hepatitis B (recombinant) vaccine | Sanofi Pasteur MSD, SNC | Hepatitis B; Meningitis, Haemophilus; Immunization | 🇪🇺 EU 1999-05-07 | Order → |
| Rotashield rotavirus vaccine | Wyeth Lederle Vaccines S.A. | Immunization; Rotavirus Infections | 🇪🇺 EU 1999-05-07 | Order → |
| Rebetol ribavirin | Merck Sharp and Dohme B.V | Hepatitis C, Chronic | 🇪🇺 EU 1999-05-06 | Order → |
| ReFacto AF moroctocog alfa | Pfizer Europe MA EEIG | Hemophilia A | 🇪🇺 EU 1999-04-13 | Order → |
| Beromun tasonermin | Belpharma s.a. | Sarcoma | 🇪🇺 EU 1999-04-12 | Order → |
| Cetrotide cetrorelix | Merck Europe B.V. | Ovulation; Ovulation Induction | 🇪🇺 EU 1999-04-12 | Order → |
| Regranex becaplermin | Janssen-Cilag International NV | Wound Healing; Skin Ulcer | 🇪🇺 EU 1999-03-29 | Order → |
| Sonata zaleplon | Meda AB | Sleep Initiation and Maintenance Disorders | 🇪🇺 EU 1999-03-12 | Order → |
| Zerene zaleplon | Meda AB | Sleep Initiation and Maintenance Disorders | 🇪🇺 EU 1999-03-12 | Order → |
| Zenapax daclizumab | Roche Registration Ltd. | Graft Rejection; Kidney Transplantation | 🇪🇺 EU 1999-02-26 | Order → |
| Infergen interferon alfacon-1 | Astellas Pharma Europe B.V. | Hepatitis C, Chronic | 🇪🇺 EU 1999-02-01 | Order → |
| Emadine emedastine | Immedica Pharma AB | Conjunctivitis, Allergic | 🇪🇺 EU 1999-01-27 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.